FRONTEO's Drug Discovery AI Factory realizes effective collaboration between biologists who have both extensive drug discovery experience in pharmaceutical companies or international research institutes and deep understanding of AI, and data scientists who perform in-depth analyses with our AI engine "KIBIT” and multiple applications powered by KIBIT.
The Drug Discovery AI Factory will continuously provide results and proposals to contribute to the improvement of efficiency, acceleration, and success rates through high novelty, high throughput, and high coverage.
Hiroyoshi Toyoshiba
Executive Officer CTO
Director, Institute for Neuro-Linguistic Science and Director, Institute for Behavioral Science
Doctor of Science
Graduated from Waseda University Graduate School of Science and Engineering Department of Mathematics. Engaged in research using statistical analysis of various data at the US National Institute of Environmental Health Sciences, and others. Developed AI algorithms for life sciences.
Makoto Miyamoto
Institute for Neuro-Linguistic Science Director,
Research Team Doctor of Agriculture
Graduated from Kyoto University graduate school. At Takeda Pharmaceutical Company Limited, he was engaged extensively in preclinical safety evaluation, special toxicity (phototoxicity) evaluation, elucidation of toxicity mechanisms, and safety biomarker searches from the early to late stages of new drug development.
Kazumi Hayashi
Institute for Neuro-Linguistic Science Senior Researcher,
Research Team Doctor of Pharmacy
After receiving his doctorate in pharmacy, he joined Yamanouchi Pharmaceutical (currently Astellas Pharma). As a research manager, he is in charge of inflammation, cardiovascular, and renal areas. He set up a drug repurposing room and engaged in DR research. He is in charge of devising analysis methods using KIBIT, planning analysis policies, analysis, and generating hypotheses.
Director in Charge of Research Team
Doctor of Science
Graduated from Waseda University and Tokyo Institute of Technology. Engaged in drug discovery basic technology development and drug discovery research at Sumitomo Chemical Co., Ltd. Engaged in drug discovery research using cutting-edge genome-related technology at the Genomic Science Institute.
Director in Charge of Research Team
M.D., Ph.
D. from the University of Kentucky College of Medicine. Engaged in research at the National Institutes of Health on biomarker measurement and method development for early diagnosis, early treatment, and new drug development for Alzheimer's disease and other cognitive-motor decline disorders.
Research Team
Doctor of Pharmacy
Engaged in synthetic discovery research of new drugs, chemoinformatics, docking simulation, etc., at Asahi Kasei Pharma Corporation. D. in HIV drug research at Nagoya City University Graduate School of Medicine and in bioactivity prediction and adverse event prediction of compounds at Graduate School of Pharmaceutical Sciences, Kyoto University. Chemist, Chemoinformatician and Data Scientist
Research Team
Researcher
Graduated from Nihon Medical and Dental University with a Master's degree, joined FRONTEO as a new graduate in April 2021, and is familiar with in-house developed AI applications that form the basis of the DD-BKM platform.
Contact us
Inquiries to the Life Science AI Business Division
Please fill in the necessary details and submit. A representative will contact you later.